Johnson Fistel, PLLP, a leading stockholder rights law firm, has initiated an investigation into the board members and executive officers of DexCom, Inc. (NASDAQ: DXCM) for potential breaches of ...

Over the last 7 days, the United States market has remained flat, yet it has risen by 5.7% over the past year with earnings forecasted to grow by 13% annually. In this environment, identifying ...

CAD (ICAD – Research Report) received a Hold rating and price target from BTIG analyst Marie Thibault today.Stay Ahead of the Market: ...

DexCom (NasdaqGS:DXCM) recently experienced a 14% price increase over the past week. This uptick coincides with the company's announcement of FDA clearance for the Dexcom G7 Continuous Glucose ...

What Johnson & Johnson and Eli Lilly are saying about Trump’s pharmaceutical tariffs, and Dexcom scores FDA approval for its ...

The global US Remote Patient Monitoring Market, valued at US$14.15 billion in 2024, is forecasted to grow at a robust CAGR of 12.8%, reaching US$29.13 billion by 2030. The growing number of elderly ...

RBC Capital lowered the firm’s price target on DexCom (DXCM) to $100 from $115 and keeps an Outperform rating on the shares as part of a ...

Wells Fargo analyst Larry Biegelsen maintained a Buy rating on Dexcom ( DXCM – Research Report) yesterday and set a price target of $98.00. The company’s shares closed yesterday at $67.39. Filter, ...

The FDA warned that several hundred units of counterfeit 1-mg semaglutide (Ozempic) were found in the U.S. drug supply chain ...

The FDA has cleared the Dexcom G7 15 Day continuous glucose monitoring system for individuals 18 years and older with ...

DexCom Inc. closed 51.60% short of its 52-week high of $139.24, which the company achieved on April 25th.

Dexcom has announced that the U.S. Food and Drug Administration has cleared its G7 15 Day Continuous Glucose Monitoring ...